Home › Compare › TGLVY vs ABBV
TGLVY yields 0.62% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, TGLVY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TGLVY + ABBV for your $10,000?
Top Glove Corporation Bhd. engages in the investment holding and provision of management services in Malaysia. The company offers medical examination, surgical, vinyl, and nitrile gloves; concentrate and synthetic latex, formers, chemicals and chemical compounds, rubber dental dams, exercise bands, condoms, and rubber related products; packaging materials, boxes, and cartons; and disposable and medical face masks, engineering parts and rubber glove machinery, functional fillers, healthcare products, and homecare and personal care products. It also provides property investment, consultancy services, and electrical engineering works; clinical and specialist medical services; analytical, emergency medical, advisory, general management, and value added services; management services in plantation sector, and processing of plantation produce; general trading; and industrial forest plantation, as well as forestry and industry services. In addition, the company trades in healthcare related products; distributes medical devices and other hospital related products; operates as a special purpose vehicle solely for issuance of Perpetual Sukuk; organizes in-house trainings and public trainings/programs; and establishes and maintains fitness related business, including healthcare, slimming centers, gymnasiums, and other related activities. Further, it generates and supplies energy and electricity using biomass technology; and offers e-commerce services for glove trading and other healthcare products. The company also exports its products to 195 countries worldwide. Top Glove Corporation Bhd. was founded in 1991 and is headquartered in Shah Alam, Malaysia.
Full TGLVY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.